We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 60

Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment
  • Bereskin & Parr LLP
  • Canada
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of


Canadian patent term extension is coming
  • Bereskin & Parr LLP
  • Canada, European Union
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian


What to expect when you are expecting to launch a drug in Canada regulatory overview
  • Bereskin & Parr LLP
  • Canada
  • March 2 2015

This article provides a brief overview of key regulatory issues to be aware of when marketing a drug in Canada. Price Regulation and Reimbursement


Securing IP in stem cells
  • Bereskin & Parr LLP
  • Canada, USA
  • April 12 2013

Stem cells are at the centre of research into regenerative medicine. They have the ability to continuously produce newly differentiated cells and


Canadian Appeal Court itching to consider patented medical treatments
  • Bereskin & Parr LLP
  • Canada
  • May 25 2015

The Canadian Federal Court of Appeal has recently indicated its interest in revisiting patentability of methods of medical treatment in future in a


Proactive pharma patent enforcement on Canadian drug combos
  • Bereskin & Parr LLP
  • Canada
  • May 14 2015

The Canadian Patented Medicine (Notice of Compliance) Regulations ("NOC Regulations") allow a patent owner to apply to Federal Court to keep a


Supreme Court dismisses appeal from the bench in Sanofi-Aventis v. Apotex, Inc.
  • Bereskin & Parr LLP
  • Canada
  • May 8 2015

On April 21st, 2015, the Supreme Court of Canada dismissed from the bench an appeal from the Federal Court of Appeal decision inApotex Inc. v


“Gene Patent” controversy comes to Canada
  • Bereskin & Parr LLP
  • Canada, USA
  • November 4 2014

Patents related to isolated DNA corresponding to a gene, as well as methods claiming the diagnostic use of such DNA sequences are often referred to


Sanofi-Aventis, et al. V. Apotex Inc., et al.
  • Bereskin & Parr LLP
  • Canada
  • November 10 2014

On October 30, the Supreme Court of Canada granted leave to appeal from the Federal Court of Appeal (FCA) decision in Apotex Inc. v. Sanofi-Aventis


Expert opinion as to what “one would expect” is speculation, not evidence
  • Bereskin & Parr LLP
  • Canada
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice